Keywords: cell, therapeutics, xyotax, misses, primary, endpoint, seattle
Cell Therapeutics' Xyotax misses primary endpoint
Article | 16 May 2005
Seattle, USA-headquartered Cell Therapeutics has posted disappointing results from two Phase III studies of Xyotax (paclitaxel poliglumex) in non-small cell ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
